Biotech, Food, Drug

The food we eat and the medicine we put into our bodies are highly regulated by a variety of government agencies. In the United States by the Food and Drug Administration (FDA) and the United States Department of Agriculture (USDA) regulate the processes by which food makes its way to the grocery store and medicine is approved for consumer use.  As the science grows more complex behind the pharmaceutical and food industry, interpretation of the regulations in place is becoming more nuanced.  Overseas, these industries are regulated by a variety of agencies; for example, the Minister of Agriculture in Canada, Centre for Food Safety in Hong Kong, and the Committee of Environmental, Public Health and Food Safety (EU), are among the many governing-bodies which regulate biotechnology, food, and drugs throughout the world.

The National Law Review is your free online resource to agency news, emerging topics in food and drug, and the latest in biotechnology updates. From nanotechnologies being used in research, to regulations of imported foods coming into the US from overseas or the development of medical devices and drugs, readers can find expert legal analysis of the developments in the industry, as well as reports on changes within the agencies that regulate these industries. The National Law Review also covers topics related to licensing, Food Safety and Inspection Services (FSIS), food and beverage regulation in the US and worldwide, nutrition labeling, and country of origin labeling guidelines.

With recent legislation being passed throughout the US in relation to marijuana use, both for recreational and medicinal purposes, readers will also find up-to-date information, litigation, and news coming from this area of interest as well. Regulations in California for labeling and proper sales of marijuana, to use in different states, or internationally, as well as rules for promoting and advertising marijuana are also covered on the site. Additionally, the development and changing landscape of tobacco use to include vaping, and how e-cigarettes and vaping are regulated, is also covered by NLR authors.

Readers who are interested in food safety, inspection, imports into the US, and regulations, these topics are covered regularly on The National Law Review as well. New legislation from the FDA, USDA, Department of Agriculture, and international bodies, are covered on the site. If you are looking for details on new nutrition-labeling regulations or health risks of consuming certain imported foods, you will find these topics, and many more, on The National Law Review.

For hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis Twitter feed, and sign up for complimentary e-news bulletins.

Custom text Title Organization Sort descending
Jun
3
2021
Federal and State Cannabis Rules Are Moving in Different Directions – Diagnosing Health Care [PODCAST] Epstein Becker & Green, P.C.
Oct
23
2018
CMS Unveils Proposed Rule Regarding Direct-to-Consumer Television Advertisements for Prescription Drug and Biological Products Epstein Becker & Green, P.C.
Dec
16
2021
CMS Issues Guidance on COVID-19 Testing in the Workplace Epstein Becker & Green, P.C.
Dec
18
2018
Mixed Results for Employers on Marijuana – Two Federal Courts Refuse to Find State Marijuana Laws Preempted by Federal Law Epstein Becker & Green, P.C.
Aug
29
2019
Will the Growing Acceptance of Cannabis Send Drug-Screening Policies Up in Smoke? Epstein Becker & Green, P.C.
Mar
7
2023
The Wait is Over . . . Or Is It? DEA’s Proposed Rules Around Telemedicine Prescribing: Initial Impressions and Key Takeaways Epstein Becker & Green, P.C.
Apr
4
2023
Unpacking Averages: FDA FOIA Response Times by Topic of Request Epstein Becker & Green, P.C.
May
9
2023
Podcast: The Legal Battle Over Mifepristone – Diagnosing Health Care [PODCAST] Epstein Becker & Green, P.C.
Jun
21
2023
Video: Employee and Health Benefits One Year After Dobbs – Employment Law This Week Epstein Becker & Green, P.C.
Sep
5
2023
FDA Issues Final Guidance on Informed Consent for IRBs, Clinical Investigators, and Sponsors Epstein Becker & Green, P.C.
Mar
19
2024
FDA and OHRP Issue Joint Draft Guidance on Content, Organization, and Presentation of Consent Forms for Research Participants Epstein Becker & Green, P.C.
Feb
13
2019
CBD “Edibles” Face Opposition from States, FDA Epstein Becker & Green, P.C.
Feb
26
2019
FDA Finalizes Two Guidance Documents Regarding Regenerative Medicine Therapies Epstein Becker & Green, P.C.
Jun
22
2022
The Pendulum Swings Both Ways: State Responses to Protect Reproductive Health Data, Post-Roe Epstein Becker & Green, P.C.
Mar
10
2015
3-D Printing Guidance Only a B-List Priority for FDA Epstein Becker & Green, P.C.
Jul
18
2019
Hawaii Decriminalizes Possession of Small Amounts of Marijuana Epstein Becker & Green, P.C.
Mar
7
2023
Comments to CMS Guidance on the Medicare Prescription Drug Inflation Rebate Program Due March 11, 2023 Epstein Becker & Green, P.C.
Jan
21
2016
No Duty to Accommodate Medical Marijuana Use in New Mexico Epstein Becker & Green, P.C.
May
2
2023
Unpacking Averages: Success Rates for FDA FOIAs by Topic and Requester Epstein Becker & Green, P.C.
May
26
2016
The Scope of FDA’s Proposed Revisions to the IND Regulations May Not Be Sufficient to Achieve Its Stated Goals Epstein Becker & Green, P.C.
Sep
5
2023
Unpacking Averages: How Accurate Do Class II Medical Devices Need to Be to Obtain 510(k) Clearance? Epstein Becker & Green, P.C.
Aug
26
2016
New FDA Draft Guidance Shows Limited Compromise with Brand and Generic Drug Manufacturers Epstein Becker & Green, P.C.
Aug
31
2016
FDA Announces November Public Hearing on Off-Label Communications: An Important Step Forward or a Signal that FDA is Headed Back to the Drawing Board? Epstein Becker & Green, P.C.
Jul
28
2020
FDA Issues Draft Guidance on Cannabis Clinical Research and Sends CBD Enforcement Discretion Guidance to OMB for Review Epstein Becker & Green, P.C.
Aug
18
2017
FDA Makes Moves to Advance Digital Health Epstein Becker & Green, P.C.
Aug
28
2017
NYC OATH Decision Finds for Medical Marijuana User Epstein Becker & Green, P.C.
Sep
18
2017
Federal Laws Do Not Preempt Connecticut Law Providing Employment Protections to Medical Marijuana Users Epstein Becker & Green, P.C.
Oct
1
2018
FDA Seeks Civil Monetary Penalties Measures to Enforce Compliance with ClinicalTrials.org Requirements Epstein Becker & Green, P.C.
Oct
29
2018
CMS Seeks to Revamp Medicare Part B Drug Reimbursement through Proposed International Pricing Index (IPI) Model Epstein Becker & Green, P.C.
Aug
11
2022
Impact of COVID-19 on Pharmacist Scope of Practice: Before and After the PREP Act – Diagnosing Health Care [Podcast] Epstein Becker & Green, P.C.
Jul
24
2019
New Jersey’s Highest Court to Decide Whether Employers Are Required to Accommodate Medical Marijuana Use Epstein Becker & Green, P.C.
Aug
12
2019
Legislative Efforts to Curb Sexual Harassment in the Hospitality Industry Finally Reach Fruition in Illinois Epstein Becker & Green, P.C.
Jul
24
2015
FDA Leverages Patient-Reported Information to Monitor Drug Safety Epstein Becker & Green, P.C.
Mar
1
2023
Unpacking Averages: Exploring New Data on FDA Responses to FOIA Requests Epstein Becker & Green, P.C.
Apr
4
2023
Is CMS Ignoring the Realities of Biopharmaceutical Costs? Epstein Becker & Green, P.C.
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins